Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle
Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
Subscribe To Our Newsletter & Stay Updated